Brokerages expect that Unum Therapeutics Inc (NASDAQ:UMRX) will announce earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Two analysts have made estimates for Unum Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.32). The firm is scheduled to issue its next earnings report on Monday, November 12th.
According to Zacks, analysts expect that Unum Therapeutics will report full year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.72) to ($1.40). For the next year, analysts expect that the company will report earnings of ($1.53) per share, with EPS estimates ranging from ($1.76) to ($1.39). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last posted its earnings results on Monday, August 13th. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $2.45 million.
Several analysts have recently weighed in on UMRX shares. Morgan Stanley boosted their target price on Unum Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Zacks Investment Research downgraded Unum Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Wedbush boosted their target price on Unum Therapeutics from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, August 14th. Finally, Cowen reissued a “hold” rating on shares of Unum Therapeutics in a report on Monday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $20.67.
Shares of Unum Therapeutics stock traded down $0.16 on Friday, hitting $9.65. The stock had a trading volume of 36,522 shares, compared to its average volume of 227,924. Unum Therapeutics has a 52-week low of $9.01 and a 52-week high of $17.66.
In other news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $12.47, for a total value of $143,217.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Several institutional investors have recently bought and sold shares of UMRX. Cowen Inc. purchased a new stake in shares of Unum Therapeutics in the 2nd quarter valued at about $8,341,000. BlackRock Inc. purchased a new stake in Unum Therapeutics during the 2nd quarter valued at approximately $6,403,000. Point72 Asset Management L.P. purchased a new stake in Unum Therapeutics during the 1st quarter valued at approximately $3,599,000. Platinum Investment Management Ltd. purchased a new stake in Unum Therapeutics during the 1st quarter valued at approximately $2,499,000. Finally, Bank of America Corp DE purchased a new stake in Unum Therapeutics during the 2nd quarter valued at approximately $1,485,000. 51.50% of the stock is owned by institutional investors and hedge funds.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
See Also: Exchange-Traded Funds (ETFs)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.